Myriad Genetics Reports Solid Q3 2024 Growth Amid Challenges
Myriad Genetics ( (MYGN) ) has released its Q3 earnings. Here is a breakdown of the information Myriad Genetics presented to its investors.
Mason company expands mental health medication services
GeneSight, a Mason-based company specializing in mental health medication, expanded its wellness services in the community.